Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Securities_and_Exchange_Commission
|
| gptkbp:acquired_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:ceo |
gptkb:Jacob_Van_Naarden
|
| gptkbp:clinical_trial |
multiple ongoing trials
|
| gptkbp:employees |
over 200
|
| gptkbp:focus_area |
oncology
|
| gptkbp:founded_in |
gptkb:2015
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
LOXO
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:market_cap |
approximately $8 billion
|
| gptkbp:notable_products |
gptkb:LOXO-292
gptkb:Vitrakvi gptkb:LOXO-101 |
| gptkbp:odimatches |
gptkb:2017
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:production_company |
gptkb:biotechnology
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research_focus |
targeted therapies
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.loxooncology.com
|
| gptkbp:bfsParent |
gptkb:Loxo_Oncology
|
| gptkbp:bfsLayer |
5
|